Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 6:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–20 of 20 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: EGFR Negative Non-Small Cell Lung Cancer Clear all
Recruiting Phase 1Phase 2 Interventional

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

NCT05579366
View directory record Official record
Conditions
High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Endometrial Cancer, Non-small Cell Lung Cancer, Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC), Mesothelioma, Breast Adenocarcinoma, Triple Negative Breast Cancer, Hormone Receptor-positive/Her2 Negative Breast Cancer, Platinum-resistant Ovarian Cancer (PROC), Platinum Sensitive Ovarian Cancer (PSOC), Primary Refractory Ovarian Cancer, Uterine Cancer
Interventions
Rina-S, Carboplatin, Bevacizumab, Pembrolizumab
Drug
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older
Enrollment
884 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
37
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Jul 23, 2026, 6:22 AM EDT
Active, not recruiting Phase 2 Interventional Results available

A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)

NCT04225117
View directory record Official record
Conditions
Locally Advanced or Metastatic Malignant Solid Tumors
Interventions
enfortumab vedotin, pembrolizumab
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
329 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
29
States / cities
Tucson, Arizona • San Francisco, California • Aurora, Colorado + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Jul 23, 2026, 6:22 AM EDT
Completed Phase 2 Interventional Results available

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

NCT02489903
View directory record Official record
Conditions
Small Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Neuroendocrine Tumors, Ovarian Epithelial Cancer
Interventions
RRx-001, Cisplatin, Etoposide, Carboplatin, Irinotecan, Vinorelbine, Doxil, Gemcitabine, Taxane, Paclitaxel, Nab-Paclitaxel, Pemetrexed
Drug
Lead sponsor
EpicentRx, Inc.
Industry
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
10
States / cities
Palo Alto, California • West Haven, Connecticut • South Bend, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2025 · Synced Jul 23, 2026, 6:22 AM EDT
Terminated Phase 1 Interventional

A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor

NCT02365662
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Triple Negative Breast Cancer, Colorectal Carcinoma, Glioblastoma Multiforme
Interventions
ABBV-221
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 99 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
3
States / cities
Boston, Massachusetts • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 29, 2018 · Synced Jul 23, 2026, 6:22 AM EDT
Completed Phase 1 Interventional

Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment

NCT01520389
View directory record Official record
Conditions
Advanced Solid Tumors, Colorectal Cancer, Squamous Cell Head and Neck Cancer, Non Small Cell Lung Cancer, Triple Negative Breast Cancer
Interventions
MM-151, MM-151 + irinotecan
Drug
Lead sponsor
Merrimack Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
4
States / cities
Aurora, Colorado • Lafayette, Indiana • Buffalo, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2018 · Synced Jul 23, 2026, 6:22 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

NCT06618287
View directory record Official record
Conditions
Lung Cancer, Breast Cancer
Interventions
BMS-986507, Osimertinib, Pembrolizumab, Nivolumab, Pumitamig
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
14
States / cities
Birmingham, Alabama • Miami, Florida • Maywood, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Jul 23, 2026, 6:22 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

NCT07070232
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
BNT326, Pumitamig, Itraconazole, Paroxetine
Drug
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
1,438 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
18
States / cities
Phoenix, Arizona • San Francisco, California • Hartford, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Jul 23, 2026, 6:22 AM EDT
Completed Phase 1 Interventional Results available

A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers

NCT01451632
View directory record Official record
Conditions
Colorectal Cancer, Squamous Cell Head and Neck Cancer, Non-small Cell Lung Cancer, Triple Negative Breast Cancer, Other Tumors With EGFR Dependence
Interventions
MM-121, Irinotecan, Cetuximab
Drug
Lead sponsor
Merrimack Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
4
States / cities
San Francisco, California • Boston, Massachusetts • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2016 · Synced Jul 23, 2026, 6:22 AM EDT
Active, not recruiting Phase 1 Interventional

Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC

NCT03611738
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Lung Cancer, Non-small Cell Lung Cancer Metastatic, Non-small Cell Lung Cancer Stage IIIB, Stage IV Non-small Cell Lung Cancer, EGFR Negative Non-Small Cell Lung Cancer
Interventions
Ceritinib, Docetaxel
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
2
States / cities
Orlando, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Jul 23, 2026, 6:22 AM EDT
Terminated Phase 2 Interventional Results available

Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations

NCT04323436
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Spartalizumab, Capmatinib, spartalizumab placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Jul 23, 2026, 6:22 AM EDT
Completed Phase 2 Interventional Results available

Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung Cancer

NCT03647488
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Capmatinib, Spartalizumab, Docetaxel
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Fayetteville, Arkansas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2022 · Synced Jul 23, 2026, 6:22 AM EDT
Completed Phase 1 Interventional

A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)

NCT02900664
View directory record Official record
Conditions
Colorectal Cancer, Triple Negative Breast Cancer, NSCLC - Adenocarcinoma
Interventions
PDR001, ACZ885, CJM112, TMT212, EGF816
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
283 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
4
States / cities
Baltimore, Maryland • Boston, Massachusetts • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2022 · Synced Jul 23, 2026, 6:22 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

NCT06682793
View directory record Official record
Conditions
Solid Tumor, Adult, Colorectal Cancer, Non-Small Cell Lung, NSCLC (Non-small Cell Lung Cancer), Cancer, Colon Cancer, Rectal Cancer, Lung Cancer, CRC, Head and Neck Squamous Cell Cancer, HNSCC, Renal Cell Carcinoma, RCC, Kidney Cancer, Triple Negative Breast Cancer, TNBC, Colorectal Adenocarcinoma
Interventions
A2B395, xT CDx with HLA-LOH assay
Biological · Diagnostic Test
Lead sponsor
A2 Biotherapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
10
States / cities
Gilbert, Arizona • La Jolla, California • Los Angeles, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Jul 23, 2026, 6:22 AM EDT
Active, not recruiting Phase 3 Interventional

Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation

NCT03833154
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Durvalumab, Placebo, (Osimertinib cohort, single-arm, open-label separate cohort)
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
724 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
80
States / cities
Tuscaloosa, Alabama • Chandler, Arizona • Phoenix, Arizona + 72 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Jul 23, 2026, 6:22 AM EDT
Active, not recruiting Phase 2 Interventional

Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Cancers of the Breast and Lung

NCT03808662
View directory record Official record
Conditions
TNBC - Triple-Negative Breast Cancer, Triple Negative Breast Cancer, NSCLC, NSCLC Stage IV, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, NSCLC Stage IV Without EGFR/ALK Mutation
Interventions
Sterotactic Body Radiotherapy/SBRT, Standard of care
Radiation · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
9
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Jul 23, 2026, 6:22 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Genetics and Shared Decision Making in Improving Care for Patients With Stage IVA-C Non-small Cell Lung Cancer

NCT03944265
View directory record Official record
Conditions
Activating ALK Gene Mutation Negative, Activating EGFR Gene Mutation Negative, Activating ROS1 Gene Mutation Negative, Health Care Provider, Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Counseling, Questionnaire Administration, Medical Chart Review
Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Jul 23, 2026, 6:22 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors

NCT05985655
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma (HNSCC), Pancreatic Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC), Platinum-resistant High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers (HGSOC), Hormone Receptor Positive [HR+] and Human Epidermal Growth Factor Receptor 2 Negative [HER2-] Breast Carcinoma, Triple Negative Breast Cancer (TNBC)
Interventions
GTAEXS617, SoC
Drug
Lead sponsor
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
4
States / cities
Los Angeles, California • Grand Rapids, Michigan • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Jul 23, 2026, 6:22 AM EDT
Completed No phase listed Observational

A Study Assessing Risk Factors for Oral Mucositis/Stomatitis and Ocular Surface Events in NSCLC and Breast Cancer

NCT06686602
View directory record Official record
Conditions
Advanced/Metastatic NSCLC, Advanced/Metastatic HER2-negative Breast Cancer
Interventions
No drug
Other
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
13,759 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced Jul 23, 2026, 6:22 AM EDT
Terminated Phase 2 Interventional

Study for Treatment With TH-4000 (Tarloxotinib) in Epidermal Growth Factor Receptor (EGFR) Mutant, T790M-negative Non-small Cell Lung Cancer (NSCLC) Patients

NCT02454842
View directory record Official record
Conditions
Non-small Cell Lung Cancer, NSCLC, Non-squamous NSCLC
Interventions
TH-4000 (Tarloxotinib)
Drug
Lead sponsor
Rain Oncology Inc
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
11
States / cities
Los Angeles, California • Santa Rosa, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2023 · Synced Jul 23, 2026, 6:22 AM EDT
Terminated Phase 2 Interventional Results available

Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung Cancer

NCT02323126
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
EGF816, INC280, Nivolumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 27, 2022 · Synced Jul 23, 2026, 6:22 AM EDT